Topical calcineurin inhibitors in the treatment of atopic dermatitis - An update on safety issues;Topische Calcineurininhibitoren bei der Behandlung der atopischen Dermatitis - Fragen zur Sicherheit: Ein Update

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 3, 2012, Pages 167-172

  Czarnecka Operacz, Magdalena ^a   Jenerowicz, Dorota ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

atopic dermatitis; pimecrolimus; safety; tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; CORTICOSTEROID THERAPY; CREAM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; OINTMENT; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84858303095     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2011.07791.x     Document Type: Review

References (42)

1. Novak N., New insights into the mechanism and management of allergic diseases: atopic dermatitis. Allergy 2009, 64: 265-75.
2. Pawankar R, Canonica GW, Holgate ST,. WAO White Book on Allergy 2011-2012: Executive Summary. World Allergy Organization 2011: 1- 16.
3. Hultsch T, Kapp A, Spergel J,. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005, 211: 174-87. (Pubitemid 41160263)
4. Cho SH, Strickland I, Boguniewicz M, Leung DY,. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001, 108: 269-74. (Pubitemid 32735412)
5. Leung AD, Schiltz AM, Hall CF, Liu AH,. Severe atopic dermatitis is associated with a high burden of environmental Staphylococcus aureus. Clin Exp Allergy 2008, 38: 789-93. (Pubitemid 351550674)
6. ThaAi D, Salgo R,. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatoven APA 2007, 2: 58-62. (Pubitemid 47020362)
7. Sulzberger MB, Witten VH, Smith CC,. Hydrocortisone (compound F) acetate ointment in dermatological therapy. J Am Med Assoc 1953, 151: 3-22.
8. Jenerowicz D, Czarnecka-Operacz M, Silny W,. Corticosteroid phobia in patients with atopic dermatitis. Wiad Lek 2005, 58: 607-15.
9. Ring J, Möhrenschlager M, Henkel V,. The US "Black Box" warning for topical calcineurin inhibitors. An ongoing controversy. Drug Safety 2008, 31: 185-98. (Pubitemid 351311575)
10. Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K,. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004, 151: 3-27. (Pubitemid 40023628)
11. Arai T, Koyama Y, Suenaga T, Honda H,. Ascomycin, an antifungal antibiotic. J Antibiotics, Series A 1962, 15: 231-2.
12. Stuetz A, Grassberger M, Meingassner JG,. Pimecrolimus (Elidel, SDZ ASM 981). Semin Cutan Med Surg 2001, 20: 233-41.
13. Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S, Paller A, de Prost Y, Puig L, Ring J, Saurat JH, Schwarz T, Shear N, Stingl G, Taieb A, Thestrup-Pedersen K,. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005, 211: 77-8. (Pubitemid 41160237)
14. McCollum A, Paik A, Eichenfeld LF,. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr Dermatol 2010, 27: 425-36.
15. ThaAi D, Salgo R,. Malignancy concerns to topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010, 28: 52-6.
16. Werfel T,. Topical use of pimecrolimus in atopic dermatitis: update on safety and efficacy. J Dtsch Dermatol Ges 2009, 9: 739-42.
17. Ormerod AD,. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005, 153: 701-5. (Pubitemid 41415894)
18. Patel TS, Greer SC, Skinner RB,. Cancer concerns with topical immunomodulators in atopic dermatitis. Am J Clin Dermatol 2007, 8: 189-94.
19. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T,. Tacrolimus (FK 506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001, 10: 519-25. (Pubitemid 32210034)
20. Ulrich C, Schmook T, Sachse M,. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004, 30: 622-7. (Pubitemid 38525892)
21. Stockfleth E, Ulrich C, Meyer T, Christophers E,. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002, 160: 251-8.
22. Elidel A. Pimecrolimus 1% cream [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2006 Jan.
23. Niwa Y, Terashima T, Sumi H,. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in the DMBA/TPA model in mice. Br J Dermatol 2004, 151: 1275-6. (Pubitemid 40030182)
24. Niwa Y, Nasr I,. Are we starting to induce cancer in order to avoid topical steroids? J Eur Acad Dermatol Venereol 2005, 19: 380-99.
25. Bonacier L, Charlesworth EN, Spergel JM, Leung DY,. The black box warning for topical celcineurin inhibitors: looking outside the box. Ann Allergy Asthma Immunol 2006, 97: 117-20. (Pubitemid 44156349)
26. Vente C, Reich K, Rupprecht R, Neumann C,. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999, 140: 338-42. (Pubitemid 29111368)
27. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, Korman NJ,. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001, 137: 747-50. (Pubitemid 32577856)
28. Allen DM, Esterly NB,. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002, 138: 1259-60. (Pubitemid 35025714)
29. Teshima D, Ikesue H, Itoh Y, Urabe K, Furue M, Oishi R,. Increased topical tacrolimus absorption in generalized leukemic erythroderma. Ann Pharmacother 2003, 37: 1444-7. (Pubitemid 37205503)
30. Pitarch G, Torrijos A, Mahquijes L, Sanchez-Carazo JL, Fortea JM,. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. Acta Derm Venereol 2006, 86: 64-5. (Pubitemid 46939794)
31. Berger TG, Duvic M, Van Voorhees A, Vanbeek MJ, Frieden IJ,. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006, 5: 818-23.
32. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M,. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004, 208: 365- 72. (Pubitemid 38736667)
33. Fleischer AB, Ling M, Eichenfeld L, Satoi Y, Jaracz E, Rico MJ, Maher RM,. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002, 47: 562-70.
34. Reitamo S, Ortonne J P, Sand C, Cambazard F, Bieber T, Fölster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C,. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005, 152: 1282-9. (Pubitemid 40933430)
35. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, Brenninkmeijer EE, Smith C, Berth-Jones J, Ruzicka T, Sharpe G, Taieb A,. 0.1% Tacrolimus Ointment Long-term Follow-up Study Group. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008, 159: 942-51.
36. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, Giannetti A, Hawk J, Hönigsmann H, Kemeny L, Luger T, Meurer M, Murphy G, Peserico A, Ranki A, Reunala T, Saurat J, Sterry W, van de Kerkhof P,. Review of the potential photo-cocarcinogeni-city of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005, 19: 663-71. (Pubitemid 41748107)
37. Mandelin J, Remitz A, Reitamo S,. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. Arch Dermatol 2010, 146: 1178-80.
38. Al-Khenaizan S,. Practical tip: Precooling topical calcineurin inhibitors tube; reduces burning sensation. Dermatol Online J 2010, 15: 16.
39. Wollenberg A, Bieber T,. Proactive therapy of atopic dermatitis-an emerging concept. Allergy 2009, 64: 276-8.
40. Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M,. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008, 63: 742-50.
41. Bieber T,. Atopic dermatitis. N Eng J Med 2008, 358: 1483-94.
42. Silny W, Czarnecka-Operacz M, Glinski W, Samochocki Z, Jenerowicz D,. Atopic dermatitis-contemporary view on pathomechanism and management. Position statement of the Polish Der-matological Society specialists. Post Dermatol Alergol 2010, 5: 365-83.